The activation of platelets in whole blood treated with ADP (20 μM) was statistically significantly higher in SP MS patients compared to the control group, which we observed in the expression of CD62P (over 60%; p < 0.001) (Fig. 1b) and PAC-1 binding (over 30%; p < 0.02) (Fig. 2b). This evidence concerns the gene SELP and myeloid sarcoma.